INVIVYD, INC. Increase (Decrease) in Prepaid Expense and Other Assets
INVIVYD, INC. (IVVD) reported Increase (Decrease) in Prepaid Expense and Other Assets of $3.73 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-13
- INVIVYD, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $1.60M.
- INVIVYD, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $2.12M.
- INVIVYD, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$7.57M, a 162.39% decline year-over-year.
- INVIVYD, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$562.00K.
- INVIVYD, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$12.92M.
- INVIVYD, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$3.19M, a 116.86% decline from fiscal 2023.
- INVIVYD, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $18.89M.
- INVIVYD, INC. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$20.37M.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 4 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 7 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $3.73M 10-Q · filed 2026-08-13 | -$3.84M derived: sum of 3 quarters · filed 2026-08-13 | -$4.40M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $2.12M 10-Q · filed 2026-05-14 | -$5.44M derived: sum of 2 quarters · filed 2026-05-14 | -$6.00M derived: sum of 3 quarters · filed 2026-05-14 | -$9.45M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | -$7.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$8.13M derived: sum of 2 quarters · filed 2026-03-05 | -$11.58M derived: sum of 3 quarters · filed 2026-08-13 | -$12.92M 10-K · filed 2026-03-05 | ||
| 2025-09-30 | -$562.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$4.01M derived: sum of 2 quarters · filed 2026-08-13 | -$5.36M 10-Q · filed 2025-11-06 | $6.77M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | -$3.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$4.80M 10-Q · filed 2026-08-13 | $7.33M derived: sum of 3 quarters · filed 2026-08-13 | -$555.00K derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | -$1.35M 10-Q · filed 2026-05-14 | $10.78M derived: sum of 2 quarters · filed 2026-05-14 | $2.89M derived: sum of 3 quarters · filed 2026-05-14 | -$518.00K derived: sum of 4 quarters · filed 2026-05-14 | ||
| 2024-12-31 | $12.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $4.24M derived: sum of 2 quarters · filed 2026-03-05 | $830.00K derived: sum of 3 quarters · filed 2026-03-05 | -$3.19M 10-K · filed 2026-03-05 | ||
| 2024-09-30 | -$7.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$11.30M derived: sum of 2 quarters · filed 2025-11-06 | -$15.31M 10-Q · filed 2025-11-06 | $3.29M derived: sum of 4 quarters · filed 2025-11-06 | ||
| 2024-06-30 | -$3.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$7.43M 10-Q · filed 2025-08-14 | $11.17M derived: sum of 3 quarters · filed 2025-08-14 | $4.83M derived: sum of 4 quarters · filed 2025-08-14 | ||
| 2024-03-31 | -$4.01M 10-Q · filed 2025-05-15 | $14.59M derived: sum of 2 quarters · filed 2025-05-15 | $8.25M derived: sum of 3 quarters · filed 2025-05-15 | $8.61M derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $18.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $12.26M derived: sum of 2 quarters · filed 2025-03-20 | $12.62M derived: sum of 3 quarters · filed 2025-03-20 | $18.89M 10-K · filed 2025-03-20 | ||
| 2023-09-30 | -$6.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$5.98M derived: sum of 2 quarters · filed 2024-11-14 | $292.00K 10-Q · filed 2024-11-14 | $2.29M derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $361.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $6.63M 10-Q · filed 2024-08-14 | $8.63M derived: sum of 3 quarters · filed 2024-08-14 | $5.09M derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2023-03-31 | $6.27M 10-Q · filed 2024-05-09 | $8.27M derived: sum of 2 quarters · filed 2024-05-09 | $4.73M derived: sum of 3 quarters · filed 2024-05-09 | -$10.89M derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$1.54M derived: sum of 2 quarters · filed 2024-03-28 | -$17.16M derived: sum of 3 quarters · filed 2024-03-28 | -$20.37M 10-K · filed 2024-03-28 | ||
| 2022-09-30 | -$3.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$19.15M derived: sum of 2 quarters · filed 2023-11-09 | -$22.37M 10-Q · filed 2023-11-09 | -$10.81M derived: sum of 4 quarters · filed 2024-02-09 | ||
| 2022-06-30 | -$15.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$18.82M 10-Q · filed 2023-08-10 | -$7.27M derived: sum of 3 quarters · filed 2024-02-09 | $2.93M derived: sum of 4 quarters · filed 2024-02-09 | ||
| 2022-03-31 | -$3.21M 10-Q · filed 2023-05-11 | $8.35M derived: sum of 2 quarters · filed 2024-02-09 | $18.54M derived: sum of 3 quarters · filed 2024-02-09 | $18.51M derived: sum of 4 quarters · filed 2024-02-09 | ||
| 2021-12-31 | $11.56M derived: 8-K 12 month − 10-Q 9 month · filed 2024-02-09 | $21.75M derived: sum of 2 quarters · filed 2024-02-09 | $21.72M derived: sum of 3 quarters · filed 2024-02-09 | $22.90M 8-K · filed 2024-02-09 | ||
| 2021-09-30 | $10.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $10.16M derived: sum of 2 quarters · filed 2022-11-10 | $11.34M 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | -$32.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $1.15M 10-Q · filed 2022-08-15 | ||||
| 2021-03-31 | $1.18M 10-Q · filed 2022-05-13 | |||||
| 2020-12-31 | $2.39M 10-K · filed 2022-03-31 | |||||
| 2020-09-30 | $47.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |